The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1577
July 29, 2019
View Complete Issue         Table of Contents 2019 
Zolgensma - One-Time Gene Therapy for Spinal Muscular Atrophy
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Zolgensma - One-Time Gene Therapy for Spinal Muscular Atrophy
July 29, 2019 (Issue: 1577)
The FDA has approved onasemnogene abeparvovec-xioi (Zolgensma – Avexis), an adeno-associated virus vector-based gene therapy, for one-time IV treatment of children <2 years old who have spinal muscular atrophy (SMA) and bi-allelic mutations...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Zolgensma - One-Time Gene Therapy for Spinal Muscular Atrophy
Article code: 1577a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.